Ignite Creation Date:
2024-05-06 @ 12:14 AM
Last Modification Date:
2024-10-26 @ 10:46 AM
Study NCT ID:
NCT01522469
Status:
COMPLETED
Last Update Posted:
2024-01-30
First Post:
2012-01-30
Brief Title:
Phase II Study of Crenolanib in Subjects With RelapsedRefractory AML With FLT3 Activating Mutations
Sponsor:
Arog Pharmaceuticals Inc
Organization:
Arog Pharmaceuticals Inc